Cesar Diaz-Garcia1, Javier Domingo2, Juan Antonio Garcia-Velasco3, Sonia Herraiz4, Vicente Mirabet5, Ignacio Iniesta6, Ana Cobo7, José Remohí8, Antonio Pellicer9. 1. IVI London, IVI-RMA global, London, United Kingdom; Fertility Preservation Unit and Reproductive Medicine Research Group, Valencia, Spain; Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain. Electronic address: cesar.diaz@ivi.uk. 2. IVI Las Palmas, IVI-RMA global, Gran Canarias, Spain. 3. IVI Madrid, IVI-RMA global, Madrid, Spain; Department of Obstetrics and Gynecology, Rey Juan Carlos University, Madrid, Spain. 4. Fertility Preservation Unit and Reproductive Medicine Research Group, Valencia, Spain; IVI Foundation, Valencia, Spain. 5. Cryopreservation Unit, Valencian Tissue Bank, Valencia, Spain. 6. Fertility Preservation Unit and Reproductive Medicine Research Group, Valencia, Spain. 7. IVI Valencia, IVI-RMA global, Valencia, Spain. 8. Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain; IVI Valencia, IVI-RMA global, Valencia, Spain. 9. Fertility Preservation Unit and Reproductive Medicine Research Group, Valencia, Spain; Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain; IVI Roma, IVI-RMA global, Rome, Italy.
Abstract
OBJECTIVE: To compare the efficacy of oocyte vitrification (OV) with that of ovarian cortex cryopreservation and transplantation (OCT) in women undergoing gonadotoxic treatments. DESIGN: Prospective observational cohort study. SETTING: Not applicable. PATIENT(S): Candidates for chemo-/radiotherapy who joined our fertility preservation (FP) program were included in this study between 2005 and 2015. One cohort included 1,024 patients undergoing OV; the other cohort included 800 patients undergoing OCT. INTERVENTION(S): OV using the cryotop device and OCT using a slow freezing protocol. MAIN OUTCOME MEASURE(S): Live-birth rate (LBR) and clinical pregnancy rate (CPR). RESULT(S): Basal antimüllerian hormone levels of the patients revealed no differences in ovarian reserve before FP (OV, 11.6 pM [5.4-24.7]; OCT, 11.8 pM [6.4-21.9]). In the OV cohort, 49 patients used the vitrified oocytes after a mean storage time of 3.9 years. In the OCT cohort, 44 sought pregnancy after a mean storage time of 5.5 years. A trend toward higher CPR and LBR (per patient) was observed in the OV group (risk ratio [RRCPR], 1.31 [95% confidence interval, 0.90-1.92]; RRLBR 1.39 [95% confidence interval, 0.95-2.03]), although differences were not statistically significant. In the OCT group, 46.7% of pregnancies occurred spontaneously and no pregnancy was achieved when the tissue was harvested beyond the age of 36 years. All patients except three undergoing OCT resumed or improved endocrine ovarian function. CONCLUSION(S): Although we observed a trend toward higher LBR after OV, OCT is a very effective method to preserve fertility, allows for natural pregnancy, and restores ovarian function. In clinical scenarios where OV is not feasible, OCT remains the FP technique of choice and should no longer be considered experimental.
OBJECTIVE: To compare the efficacy of oocyte vitrification (OV) with that of ovarian cortex cryopreservation and transplantation (OCT) in women undergoing gonadotoxic treatments. DESIGN: Prospective observational cohort study. SETTING: Not applicable. PATIENT(S): Candidates for chemo-/radiotherapy who joined our fertility preservation (FP) program were included in this study between 2005 and 2015. One cohort included 1,024 patients undergoing OV; the other cohort included 800 patients undergoing OCT. INTERVENTION(S): OV using the cryotop device and OCT using a slow freezing protocol. MAIN OUTCOME MEASURE(S): Live-birth rate (LBR) and clinical pregnancy rate (CPR). RESULT(S): Basal antimüllerian hormone levels of the patients revealed no differences in ovarian reserve before FP (OV, 11.6 pM [5.4-24.7]; OCT, 11.8 pM [6.4-21.9]). In the OV cohort, 49 patients used the vitrified oocytes after a mean storage time of 3.9 years. In the OCT cohort, 44 sought pregnancy after a mean storage time of 5.5 years. A trend toward higher CPR and LBR (per patient) was observed in the OV group (risk ratio [RRCPR], 1.31 [95% confidence interval, 0.90-1.92]; RRLBR 1.39 [95% confidence interval, 0.95-2.03]), although differences were not statistically significant. In the OCT group, 46.7% of pregnancies occurred spontaneously and no pregnancy was achieved when the tissue was harvested beyond the age of 36 years. All patients except three undergoing OCT resumed or improved endocrine ovarian function. CONCLUSION(S): Although we observed a trend toward higher LBR after OV, OCT is a very effective method to preserve fertility, allows for natural pregnancy, and restores ovarian function. In clinical scenarios where OV is not feasible, OCT remains the FP technique of choice and should no longer be considered experimental.
Authors: Alexandra Higgins; Zaraq Khan; Charles C Coddington; Shahrukh K Hashmi; Mehrdad Hefazi; Hassan Alkhateeb; Mark R Litzow; William J Hogan; Elizabeth Cathcart-Rake; Carrie A Thompson; Mrinal M Patnaik Journal: Biol Blood Marrow Transplant Date: 2019-02-15 Impact factor: 5.742
Authors: Fatemeh Anbari; Mohammad Ali Khalili; Maryam Mahaldashtian; Alireza Ahmadi; Maria Grazia Palmerini Journal: Turk J Obstet Gynecol Date: 2022-06-27
Authors: Esther H Chung; Stephanie L Lim; Evan Myers; Haley A Moss; Kelly S Acharya Journal: J Assist Reprod Genet Date: 2021-05-11 Impact factor: 3.357
Authors: Kutluk H Oktay; Loris Marin; Boris Petrikovsky; Michael Terrani; Samir N Babayev Journal: Trends Mol Med Date: 2021-02-04 Impact factor: 15.272
Authors: Valentino Martelli; Maria Maddalena Latocca; Tommaso Ruelle; Marta Perachino; Luca Arecco; Kristi Beshiri; Maria Grazia Razeti; Marco Tagliamento; Maurizio Cosso; Piero Fregatti; Matteo Lambertini Journal: Breast Cancer (Dove Med Press) Date: 2021-05-24
Authors: Charlotte Sonigo; Nelly Frydman; Anne Mayeur; Vincent Puy; Victoria Windal; Laetitia Hesters; Vanessa Gallot; Alexandra Benoit; Michael Grynberg Journal: J Assist Reprod Genet Date: 2021-04-01 Impact factor: 3.357